Exploring the role of microbiota in lung cancer treatment
Characterization of Microbiota (intestinal, from Lungs, and Upper Airways) in Patients with Non-small Cell Lung Carcinoma: Exploratory Study
This study is testing how the bacteria in the lungs and throat of patients with non-small cell lung cancer might affect their treatment outcomes when they have surgery alone or surgery with chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Centre Jean Perrin Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Clermont Ferrand, Puy de Dôme) |
| Trial ID | NCT03068663 on ClinicalTrials.gov |
What this trial studies
This study investigates the lung and upper airway microbiota in patients with non-small cell lung cancer. It involves two groups: one receiving surgery only and the other receiving both chemotherapy and surgery. Patients will provide various biological samples, including saliva, fecal, and lung tissue, to analyze changes in microbiota and their potential associations. The findings aim to inform future studies on manipulating microbiota to enhance cancer treatment tolerance and effectiveness.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with non-small cell lung carcinoma who are eligible for surgery or chemotherapy followed by surgery.
Not a fit: Patients with cognitive difficulties or those currently undergoing treatment with antibiotics, corticosteroids, or immunosuppressants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for lung cancer by leveraging microbiota manipulation.
How similar studies have performed: While the role of microbiota in cancer treatment is an emerging field, similar studies have shown promising results in other cancer types, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * non small cell lung carcinoma patient suitable for surgery, or chemotherapy followed by surgery * BMI \<29.9 kg/m² * not taking antibiotics, corticosteroids and/or immunosuppressants at least during two months before inclusion * not taking prebiotics, probiotics or symbiotics at least during two months before inclusion * signing the written consent before enrollment in the study * affiliation to the national health insurance (or system alike) according to the law from 9th August 2004 Exclusion Criteria: * cognitive difficulties * refusal of participation or inability to give a clear consent * digestive or pulmonary infection of a long duration during the two months preceding the study (with antibiotic treatment) * inflammatory digestive pathology * concurrent treatment with experimental medication, participation in another clinical therapeutic study within 30 days * presence of colostomy, total or partial gastrectomy * previous esophageal surgery * previous ORL (otho-rhino-laryngo) cancer treated by radiotherapy or surgery * patient enable to follow the requirements of the study * patient deprived of his rights by administrative or judicial decision
Where this trial is running
Clermont Ferrand, Puy de Dôme
- Centre Jean Perrin — Clermont Ferrand, Puy de Dôme, France (Recruiting)
Study contacts
- Principal investigator: Marc Filaire, MD, Pr — Service de Chirurgie Thoracique, Centre Jean Perrin
- Study coordinator: Marc Filaire, MD, Pr
- Email: marc.filaire@clermont.unicancer.fr
- Phone: 0473278121
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.